Wednesday, November 9, 2011

Xoma, partner Servier to expand eye disease trial

Xoma Ltd. and French drug partner Les Laboratoires Servier will broaden their late-stage clinical program to include patients diagnosed with a group of non-infectious eye maladies.
The Phase III trial of XOMA-052, also known as gevokizumab, had focused on Behcet’s uveitis, an eye disease that affects about 7,500 patients in the United States. By including several eye diseases categorized as non-infectious uveitis, including Behcet’s, the potential number of patients is increased to more than 150,000, the Berkeley-based company (NASDAQ: XOMA) said.

No comments:

Post a Comment

Post a Comment